Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
2.02
Dollar change
+0.02
Percentage change
1.00
%
Index- P/E- EPS (ttm)-1.07 Insider Own32.41% Shs Outstand67.71M Perf Week-6.48%
Market Cap137.38M Forward P/E- EPS next Y-1.69 Insider Trans-0.09% Shs Float45.97M Perf Month24.69%
Income-71.09M PEG- EPS next Q-0.73 Inst Own70.51% Short Float9.94% Perf Quarter2.02%
Sales398.00M P/S0.35 EPS this Y-525.00% Inst Trans32.39% Short Ratio2.31 Perf Half Y-86.42%
Book/sh4.77 P/B0.42 EPS next Y43.25% ROA-17.23% Short Interest4.57M Perf Year-90.88%
Cash/sh5.49 P/C0.37 EPS next 5Y- ROE-21.00% 52W Range1.58 - 25.48 Perf YTD-86.28%
Dividend Est.- P/FCF8.90 EPS past 5Y- ROI-21.82% 52W High-92.07% Beta-0.63
Dividend TTM- Quick Ratio4.48 Sales past 5Y2300.59% Gross Margin65.39% 52W Low28.25% ATR (14)0.16
Dividend Ex-DateMar 28, 2018 Current Ratio4.48 EPS Y/Y TTM32.69% Oper. Margin-20.42% RSI (14)52.76 Volatility8.83% 8.63%
Employees384 Debt/Eq0.01 Sales Y/Y TTM324.95% Profit Margin-17.86% Recom2.71 Target Price4.25
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-7986.04% Payout0.00% Rel Volume0.49 Prev Close2.00
Sales Surprise-9.91% EPS Surprise-43650.00% Sales Q/Q24.10% EarningsMay 09 BMO Avg Volume1.98M Price2.02
SMA205.40% SMA5010.62% SMA200-78.86% Trades Volume966,373 Change1.00%
Date Action Analyst Rating Change Price Target Change
Mar-18-24Downgrade Mizuho Buy → Neutral $32 → $4
Mar-11-24Downgrade Robert W. Baird Outperform → Neutral $37 → $4
Mar-11-24Downgrade Leerink Partners Outperform → Market Perform $27 → $4
Mar-08-24Downgrade Goldman Buy → Neutral
Mar-08-24Downgrade Evercore ISI Outperform → In-line
Jan-03-24Initiated Robert W. Baird Outperform $37
Dec-12-23Initiated Deutsche Bank Buy $36
Jul-24-23Upgrade Goldman Neutral → Buy $45 → $49
Mar-31-23Initiated Mizuho Buy $52
Jan-05-23Initiated BofA Securities Buy $50
Jul-10-24 10:53AM
07:00AM
03:00AM
Jul-09-24 04:01PM
Jun-28-24 11:02AM
09:00AM Loading…
Jun-04-24 09:00AM
May-14-24 07:25AM
May-10-24 03:54PM
12:47PM
May-09-24 08:15AM
07:00AM
May-08-24 09:00AM
May-02-24 09:00AM
Apr-30-24 12:02PM
Apr-10-24 03:14PM
09:00AM Loading…
09:00AM
Apr-08-24 09:00AM
Apr-04-24 01:20PM
10:05AM
07:52AM
07:43AM
07:07AM
07:00AM
06:09AM
Apr-03-24 05:45AM
Apr-01-24 07:30PM
Mar-27-24 07:36AM
Mar-25-24 02:33PM
Mar-14-24 06:49PM
09:00AM
10:00AM Loading…
Mar-13-24 10:00AM
09:03AM
Mar-12-24 07:55AM
Mar-11-24 12:34PM
07:45AM
Mar-10-24 08:00AM
Mar-08-24 06:27PM
04:05PM
11:30AM
10:20AM
10:12AM
09:38AM
09:26AM
07:07AM
07:00AM
02:05AM
Feb-27-24 05:45AM
Feb-26-24 11:39AM
Feb-25-24 06:30AM
Feb-23-24 04:05PM
10:30AM
10:10AM
09:00AM
05:45AM
Feb-22-24 06:57PM
04:10PM
08:15AM
07:35AM
07:00AM
Feb-20-24 05:45AM
Feb-19-24 12:40PM
Feb-15-24 04:05PM
02:13PM
09:00AM
Feb-13-24 09:16PM
12:58PM
Feb-12-24 08:09PM
11:09AM
Feb-08-24 09:00AM
Jan-26-24 03:57PM
Jan-21-24 01:16PM
Jan-14-24 12:54PM
Jan-05-24 05:34AM
Dec-26-23 07:02PM
08:48AM
Dec-22-23 09:00AM
Dec-11-23 08:36AM
Dec-04-23 09:00AM
Nov-29-23 05:15PM
Nov-28-23 08:48AM
07:00AM
Nov-27-23 09:00AM
Nov-21-23 09:00AM
Nov-12-23 11:59AM
Nov-10-23 12:26AM
Nov-09-23 05:04PM
12:12PM
08:05AM
07:00AM
Nov-04-23 12:16PM
Nov-02-23 10:00AM
09:00AM
Oct-19-23 09:00AM
Oct-18-23 08:30AM
Oct-13-23 08:26AM
07:55AM
07:45AM
Oct-11-23 08:07AM
Oct-10-23 09:45AM
09:12AM
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quimi DaphneDirectorMay 15 '24Buy1.892,2504,2525,000May 16 07:37 PM
Mazzariello GinaChief Legal OfficerMay 15 '24Sale1.8810,45519,654151,477May 16 07:36 PM
Quimi DaphneDirectorMay 14 '24Buy1.892,7505,1842,750May 16 07:37 PM
Klee Justin B.Co-Chief Executive OfficerMar 05 '24Sale18.734,13577,4402,959,308Mar 07 04:05 PM
Cohen Joshua BCo-Chief Executive OfficerMar 05 '24Sale18.734,13577,4403,023,002Mar 07 04:05 PM
FRATES JAMES MChief Financial OfficerMar 05 '24Sale18.731,79233,560134,784Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerMar 05 '24Sale18.731,54028,84181,372Mar 07 04:05 PM
Mazzariello GinaChief Legal OfficerFeb 23 '24Sale18.762,83853,23146,245Feb 27 05:59 PM
Klee Justin B.Co-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,836,776Jan 11 05:11 PM
Cohen Joshua BCo-Chief Executive OfficerJan 09 '24Sale16.335,84195,3722,900,470Jan 11 05:10 PM
Yeramian Patrick DChief Medical OfficerJan 09 '24Sale16.332,81245,915205,605Jan 11 05:04 PM
FRATES JAMES MChief Financial OfficerJan 09 '24Sale16.332,71644,347112,035Jan 11 05:11 PM
Olinger MargaretChief Commercial OfficerDec 27 '23Option Exercise0.3725,0009,250276,108Dec 29 04:07 PM
Firestone KarenDirectorDec 15 '23Buy14.974,00059,8805,000Dec 19 04:37 PM
Cohen Joshua BCo-Chief Executive OfficerNov 16 '23Option Exercise1.5763,694100,0002,906,311Nov 20 08:20 PM
FRATES JAMES MChief Financial OfficerAug 23 '23Option Exercise6.8818,165124,975106,341Aug 24 04:15 PM
Mazzariello GinaChief Legal OfficerAug 15 '23Sale20.886,164128,68649,083Aug 17 04:35 PM